Kyle Doherty

GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

Charles Swanton, FRCP, BSc, PhD, has a craving to understand cancer’s evolution, and his list of achievements can prove it.

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

The NCCN has updated its guidelines for soft tissue sarcoma to include nirogacestat as a systemic therapy option for patients with desmoid tumors.

Expert oncologists who treat patients with advanced renal cell carcinoma discuss updates from clinical trials presented during the 2023 ESMO Congress.

Although the severity of the shortage of chemotherapy agents, particularly with the platinum-based therapies cisplatin and carboplatin, has receded from the heights seen earlier in 2023, clinicians are still dealing with its ramifications and having to strategically manage how they employ certain chemotherapies.

Charles S. Kamen, PhD, MPH, discusses key developments and efforts that are planned and underway to further the progress that has been observed in terms of increasing cancer equity in sexual and gender minority individuals.

The 2023 ESMO Congress took place October 20 to 24 in Madrid, Spain, with global perspectives on groundbreaking data. We break down some of the key highlights from the annual meeting that oncology fellows should absorb, and apply to practice, as soon as possible.

In a full-circle scenario, Cedars-Sinai Cancer, based in Los Angeles, California, welcomed back Margaret Liang, MD, MSHPM, in July 2023 to the institution where she completed her fellowship.

The FDA has accepted and granted priority review to the biologics license application seeking the approval of the HER3-directed antibody-drug conjugate patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

The implementation and subsequent optimization of a health information technology module within the electronic health record has allowed clinicians across a diverse health care system to identify barriers to improve discrete capture of cancer staging and design solutions to address them.

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.

Tucatinib, which inhibits phosphorylation of HER2/3 resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, has shown promise for patients with brain metastases as the small molecule inhibitor of HER2 can cross the blood-brain barrier.

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

The presence of mutated SRSF2 in knock-in mouse models of JAK2 V617F–driven myeloproliferative neoplasms reduced the rate of polycythemia and hampered hematopoietic progenitor functions.

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.

Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.

Golidocitinib displayed antitumor activity and an acceptable safety profile in patients with refractory/relapsed peripheral T-cell lymphoma, according to data from the pivotal phase 2 JACKPOT8 study.

Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

Shortages of several anticancer drugs continue to negatively impact clinicians’ ability to deliver the best possible care to patients.

Significant progress has been made in terms of understanding myeloproliferative neoplasms and developing treatment strategies to combat them.

Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.

Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.

Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.